| You
are here: Home: BCU
Surgeons Vol.2 Issue 3: Gershon
Locker, MD: Select publications
Select publications
Anastrozole, Tamoxifen, Alone or in Combination (ATAC Trial)
ATAC Trialists’ Group. Anastrozole alone or in combination
with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal
women with
early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359:2131-2139.
Abstract
Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant
breast cancer trial in postmenopausal patients: Factors influencing the success
of patient recruitment. Eur J Cancer 2002;38:1984–1986. Abstract
Buzdar A. Anastrozole as Adjuvant Therapy for Early-Stage Breast
Cancer: Implications of the ATAC Trial. Clin Breast Cancer 2003;4 Suppl 1:S42-8. Abstract
Buzdar A et al. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination)
trial in postmenopausal women with early breast cancer — Updated efficacy
results based on a median follow-up of 47 months. Breast Cancer Res Treat 2002;
Abstract
13.
Chung CT, Carlson RW. The role of aromatase inhibitors in early breast
cancer. Curr Treat Options Oncol 2003;4(2):133-40. Abstract
Klijn J, for the ATAC Trialists’ Group. The ATAC (anastrozole,
Tamoxifen, Alone or in Combination) trial: An efficacy update, focusing on
breast cancer
(BC) events, based on a median follow-up of 47 months. Proc ASCO 2003:Abstract
338.
Ligibel JA, Winer EP. Clinical differences among the aromatase inhibitors. Clin Cancer Res 2003;9(1 Pt 2):473S-9S. Abstract
Locker GY et al. The time course of bone fractures observed in the
ATAC (‘Arimidex’,
Tamoxifen, Alone or in Combination) trial. Proc ASCO 2003:Abstract
98.
Sainsbury R on behalf of the ATAC Trialists' Group. Beneficial side-effect
profile of anastrozole compared with tamoxifen confirmed by additional 7 months
of exposure data: A safety update from the ’Arimidex’, Tamoxifen,
Alone or in Combination (ATAC) trial. Breast Cancer Res Treat 2002;Abstract
633.
Winer EP et al. American Society of Clinical Oncology Technology
Assessment Working Group Update: Use of aromatase inhibitors in the adjuvant
setting. J Clin Oncol 2003;21(13). Abstract
|
